Yamo Pharma's L1-79 Poised to Become First FDA-Approved Autism Treatment, Enters Phase 2 Clinical Trials

Odaily News: Bloomberg ETF analyst Eric Balchunas posted on X platform that Defiance CEO and ASD issuer Matt Bielski said Yamo Pharma's L1-79 "changed lives," as his 4-year-old son Lev has severe autism. L1-79 is currently in Phase 2 clinical trials and is poised to become the first FDA-approved autism treatment; approximately 1 in every 31 children in the United States is diagnosed with autism, including Bielski's youngest son.